摘要
目的:评价齐拉西酮与阿立哌唑治疗女性首发精神分裂症的疗效与不良反应。方法:31例符合CCMD-3精神分裂症诊断标准的女性首发患者随机分为阿立哌唑(博思清)组(36例)和齐拉西酮(思贝格)组(35例),采用阳性症状与阴性症状量表(positive symptoms and negative symptoms scale,PANSS)评定疗效,副反应量表(treatment Emergent Symptom Scale,TESS)评价药物安全性。结果:两组患者治疗前及治疗后2、4、8PANSS评分差异无显著性(P>0.05),两组均无严重不良反应。结论:阿立哌唑和齐拉西酮治疗女性首发精神分裂症有效,且不良反应少。
Objective： To evaluate the efficacy and adverse reactions of aripiprazole and ziprasidone in female first-onset schlzophrenia.Method： 31 female first-onset schizophrenia patients met the CCMD-3 diagnosis of schizophrenia were randomly assigned to aripiprazole group （36 patients） and ziprasidone group （35 cases）. Positive symptoms and negative syndrome scale（PANSS） and treatment Emergent Symptom Scale（TESS） were used to evaluate the efficacy and safety.Result： There was no significant difference in PANSS scores（P〉0.05） before and after 2, 4, 8 week＇ treatment between two groups. The two groups had no serious adverse reactions.Conclusion： Aripiprazole and ziprasidone were effective and less adverse reactions in treatment of female first-onset schizophrenia.
出处
《中外医学研究》
2013年第33期15-16,共2页
CHINESE AND FOREIGN MEDICAL RESEARCH
